MODEL VERDICT
The Oncology Institute, Inc. (TOI)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| Jun 12, 2026 | NEUTRAL | 0.15 | $5.31 | CURRENT | — |
| Jun 5, 2026 | NEUTRAL | 0.14 | $4.87 | CURRENT | — |
| May 29, 2026 | NEUTRAL | 0.14 | $4.69 | CURRENT | — |
| May 22, 2026 | NEUTRAL | 0.14 | $4.59 | CURRENT | — |
| May 15, 2026 | NEUTRAL | 0.14 | $3.98 | CURRENT | — |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| EV To Revenue 5 industry peers | $1.18 | -77.8% | 4% | B | Data |
| Price / Sales 5 industry peers | $1.10 | -79.3% | 3% | B | Model Driven |
| Weighted Output Blended model output | $1.13 | -78.6% | 100% | 59 | SIGNIFICANTLY OVERVALUED |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 5.73 | 4.72 | 1.59 | 10.89 | 4.73 |
| P/B Ratio | 7.82 | 6.20 | 1.08 | 22.72 | 8.64 |
| P/S Ratio | 2.36 | 1.85 | 0.06 | 6.54 | 2.51 |
Based on our peer multiples analysis with 5 valuation metrics, the model estimates TOI's fair value at $1.13 vs the current price of $5.31, implying -78.6% downside potential. Model verdict: Significantly Overvalued. Confidence: 59/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $1.13 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $0.74 (P10) to $1.68 (P90), with a median of $1.19.
TOI's current P/E of -9.8x compares to the industry median of 19.6x (4 peers in the group). This represents a -150.1% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
5 analysts cover TOI with a consensus rating of Buy. The consensus price target is $8.00 (range: $8.00 — $8.00), implying +50.7% upside from the current price. Grade breakdown: Strong Buy (0), Buy (5), Hold (0), Sell (0), Strong Sell (0).
The model confidence score is 59/100, based on: data completeness (6), peer quality (22), historical depth (16), earnings stability (5), and model agreement (10). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for TOI.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.